Christhardt Kohler

Prof. Dr. Christhardt Kohler


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
Christhardt KohlerChristhardt Kohler
Christhardt Kohler
HHHermann Hertel
Hermann Hertel
JHJörg Herrmann
Jörg Herrmann
SMSimone Marnitz
Simone Marnitz
PMPeter Mallmann
Peter Mallmann
ASAchim Schneider
Achim Schneider
Objective Laparoscopic/robotic radical hysterectomy has been historically considered oncologically equivalent to open radical hysterectomy for patients with early cervical cancer. However, a recent prospective randomized trial (Laparoscopic Approach to Cervical Cancer, LACC) has demonstrated significant inferiority of the minimally invasive approach. The aim of this study is to evaluate the oncologic outcomes of combined laparoscopic-vaginal radical hysterectomy. Methods Between August 1994 and December 2018, patients with invasive cervical cancer were treated using minimally-invasive surgery at the Universities of Jena, Charité Berlin (Campus CCM and CBF) and Cologne and Asklepios Clinic Hamburg. 389 patients with inclusion criteria identical to the LACC trial were identified. In contrast to the laparoscopic/robotic technique used in the LACC trial, all patients in our cohort underwent a combined transvaginal-laparoscopic approach without the use of any uterine manipulator. Results A total of 1952 consecutive patients with cervical cancer were included in the analysis. Initial International Federation of Gynecology and Obstetrics (FIGO) stage was IA1 lymphovascular space invasion (LVSI+), IA2 and IB1/IIA1 in 32 (8%), 43 (11%), and 314 (81%) patients, respectively, and histology was squamous cell in 263 (68%), adenocarcinoma in 117 (30%), and adenosquamous in 9 (2%) patients. Lymphovascular invasion was confirmed in 106 (27%) patients. The median number of lymph nodes was 24 (range 2–86). Lymph nodes were tumor-free in 379 (97%) patients. Following radical hysterectomy, 71 (18%) patients underwent adjuvant chemoradiation or radiation. After a median follow-up of 99 (range 1–288) months, the 3-, 4.5-, and 10-year disease-free survival rates were 96.8%, 95.8%, and 93.1 %, and the 3-, 4.5-, and 10-year overall survival rates were 98.5%, 97.8%, and 95.8%, respectively. Recurrence location was loco-regional in 50% of cases with recurrence (n=10). Interestingly, 9/20 recurrences occurred more than 39 months after surgery. Conclusion The combined laparoscopic-vaginal technique for radical hysterectomy with avoidance of spillage and manipulation of tumor cells provides excellent oncologic outcome for patients with early cervical cancer. Our retrospective data suggest that laparoscopic-vaginal surgery may be oncologically safe and should be validated in further randomized trials.

1 August 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
Christhardt KohlerChristhardt Kohler
Christhardt Kohler
POPeter Oppelt
Peter Oppelt
GFGiovanni Favero
Giovanni Favero
BMBernd Morgenstern
Bernd Morgenstern
IRIngo Runnebaum
Ingo Runnebaum
SMSimone Marnitz
Simone Marnitz

22 February 2015 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Pirus GhadjarPirus Ghadjar
Pirus Ghadjar
VBVolker Budach
Volker Budach
Christhardt KohlerChristhardt Kohler
Christhardt Kohler
AJAndreas Jantke
Andreas Jantke
SMSimone Marnitz
Simone Marnitz
Young patients with cervical cancer who undergo chemoradiation might be interested in fertility preservation, not only dependent upon the use of a gestational carrier as maybe achieved by the use of ovarian transposition and cryo-conservation of oocytes or ovarian tissue, but may prefer to carry pregnancy to term after cancer treatment. The latter approach is a non-established concept needing both modern radiation therapy approaches as well as modifications -if at all possible- in current recommendations for target volume delineation to spare dose to the unaffected uterus. Future strategies to serve selected patients in this respect should only be conducted in prospective clinical evaluations and are critically discussed in this article.

13 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DCDavid Cibula
David Cibula
MBMartina Borčinová
Martina Borčinová
SMSimone Marnitz-Schulze
Simone Marnitz-Schulze
JJJiří Jarkovský
Jiří Jarkovský
JKJaroslav Klát
Jaroslav Klát
RKRoman Kocian
Roman Kocian
Background: To prospectively assess LLL incidence among cervical cancer patients treated by uterine surgery complemented by SLN biopsy, without PLND. Methods: A prospective study in 150 patients with stage IA1–IB2 cervical cancer treated by uterine surgery with bilateral SLN biopsy. Objective LLL assessments, based on limb volume increase (LVI) between pre- and postoperative measurements, and subjective patient-perceived swelling were conducted in six-month periods over 24-months post-surgery. Results: The cumulative incidence of LLL at 24 months was 17.3% for mild LLL (LVI 10–19%), 9.2% for moderate LLL (LVI 20–39%), while only one patient (0.7%) developed severe LLL (LVI > 40%). The median interval to LLL onset was nine months. Transient edema resolving without intervention within six months was reported in an additional 22% of patients. Subjective LLL was reported by 10.7% of patients, though only a weak and partial correlation between subjective-report and objective-LVI was found. No risk factor directly related to LLL development was identified. Conclusions: The replacement of standard PLND by bilateral SLN biopsy in the surgical treatment of cervical cancer does not eliminate the risk of mild to moderate LLL, which develops irrespective of the number of SLN removed.

2 May 2022 in Gynecologic Oncology
Verified
Journal Article
Closed access
CRCarlo Ronsini
Carlo Ronsini
Christhardt KohlerChristhardt Kohler
Christhardt Kohler
PFPasquale De Franciscis
Pasquale De Franciscis
MVMarco La Verde
Marco La Verde
LMLavinia Mosca
Lavinia Mosca
NCNicola Colacurci
Nicola Colacurci

20 February 2024 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
Nicolò BizzarriNicolò Bizzarri
Nicolò Bizzarri
AOAndreas Obermair
Andreas Obermair
HHHeng-Cheng Hsu
Heng-Cheng Hsu
ECEnrique Chacon
Enrique Chacon
ACAnna Collins
Anna Collins
PRPedro T Ramirez
Pedro T Ramirez
Objective The purpose of this study was to establish a consensus on the surgical technique for sentinel lymph node (SLN) dissection in cervical cancer. Methods A 26 question survey was emailed to international expert gynecological oncology surgeons. A two-step modified Delphi method was used to establish consensus. After a first round of online survey, the questions were amended and a second round, along with semistructured interviews was performed. Consensus was defined using a 70% cut-off for agreement. Results Twenty-five of 38 (65.8%) experts responded to the first and second rounds of the online survey. Agreement ≥70% was reached for 13 (50.0%) questions in the first round and for 15 (57.7%) in the final round. Consensus agreement identified 15 recommended, three optional, and five not recommended steps. Experts agreed on the following recommended procedures: use of indocyanine green as a tracer; superficial (with or without deep) injection at 3 and 9 o’clock; injection at the margins of uninvolved mucosa avoiding vaginal fornices; grasping the cervix with forceps only in part of the cervix is free of tumor; use of a minimally invasive approach for SLN biopsy in the case of simple trachelectomy/conization; identification of the ureter, obliterated umbilical artery, and external iliac vessels before SLN excision; commencing the dissection at the level of the uterine artery and continuing laterally; and completing dissection in one hemi-pelvis before proceeding to the contralateral side. Consensus was also reached in recommending against injection at 6 and 12 o’clock, and injection directly into the tumor in cases of the tumor completely replacing the cervix; against removal of nodes through port without protective maneuvers; absence of an ultrastaging protocol; and against modifying tracer concentration at the time of re-injection after mapping failure. Conclusion Recommended, optional, and not recommended steps of SLN dissection in cervical cancer have been identified based on consensus among international experts. These represent a surgical guide that may be used by surgeons in clinical trials and for quality assurance in routine practice.